News
OpTiMus: A Novel Transgenic Mouse Platform for Discovery of Fully Human Therapeutic-Grade TCRs and Generation of Bispecific T Cell Engagers
This presentation has been presented at: 5th Annual TCR-Based Therapies for Solid Tumours Summit, Boston on 24th March 2024 by E-Chiang Lee (Ex VP Research) Immuno-Oncology Summit, Europe on 25th March 2024 by Wei Wang (Snr Director of Technology)
Read More
David Hung Joins T-Therapeutics
Dr David Hung has joined T-Therapeutics as Chairman of its Board of Directors. In this video, which accompanied the announcement, Dr Hung explains his decision: “I have always wanted to be on the cutting-edge of science and transform the practice of medicine. I…
Read More
T-Therapeutics appoints Dr David Hung as Chairman
Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development of the company’s pipeline of TCR-based immuno-oncology drugs 12 June 2024; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble TCR therapeutics targeting cancer and autoimmune indications, today announces…
Read More
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines…
Read More
